Pierre SAINTIGNY

Le Dr. Pierre Saintigny est oncologue médical, médecin spécialiste de Centres de Lutte Contre le Cancer, très impliqué dans le développement de programmes de recherche translationnelle au Centre Léon Bérard à Lyon. Il est rattaché au Département de Médecine ainsi qu’à l’équipe d’Alain Puisieux (EMT et plasticité des cellules cancéreuses) au sein du Centre de Recherche en Cancérologie de Lyon. Il appartient également au Département de Recherche Translationnelle et de l’Innovation en y assurant la direction du Laboratoire de Recherche Translationnelle et la coordination scientifique de l’Unité de Caractérisation Tumorale. Ces projets de recherche se concentrent sur les cancers pulmonaires et des voies aérodigestives supérieures. Il participe activement au développement du programme AURAGEN dans le contexte du Plan France Médecine Génomique 2025.Publications sélectionnées.

Pierre Saintigny is a medical oncologist and physician-scientist at Centre Léon Bérard in Lyon, heavily involved in the development of translational research programs. He is affiliated to the Department of Medical Oncology, to Alain Puisieux’ team (EMT and Cancer Cell Plasticity) at Cancer Research Center of Lyon and to the Department of Translational Research and Innovation where he is the Director of the Laboratory of Translational Research and coordinates the Unit of Tumor Characterization. He is focusing his research on the lung and head and neck field. He is actively involved in the large scale sequencing program AURAGEN in the context of Plan France Médecine Génomique 2025.

Publications sélectionnées

1. Saintigny P, William WN Jr., Foy JP, Papadimitrakopoulou V, Lang W, Zhang L, Fan YH, Feng L, Kim ES, El-Naggar AK, Lee JJ, Mao L, Hong WK, Lingen MW, Lippman SM. Met receptor tyrosine kinase and chemoprevention of oral cancer. J Natl Cancer Inst, in press.
2. Foy JP, Bazire L, Ortiz-Cuaran S, Deneuve S, Kielbassa J, Thomas E, Viari A, Puisieux A, Bertolus C, Foray N, Kirova Y, Verrelle P, Saintigny P. A 13-gene expression based radioresistant score is associated with specific molecular features of HPV-negative head and neck squamous cell carcinomas and is predictive of the benefit of radiotherapy. BMC Medicine. 2017 Sep 1;15(1):165.
3. Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, Albaret MA, Ortiz-Cuaran S, Thomas E, Colombe A, Py C, Gadot N, Michot JP, Fayette J, Viari A, Van den Eynde B, Goudot P, Devouassoux-Shisheboran M, Puisieux A, Caux C, Zrounba P, Lantuejoul S, Saintigny P. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Ann Oncol. 2017 Aug 1;28(8):1934-1941.
4. Foy JP, Tortereau A, Caulin C, Le Texier V, Lavergne E, Thomas E, Chabaud S, Perol D, Lachuer J, Lang W, Hong WK, Goudot P, Lippman SM, Bertolus C, Saintigny P. The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer. Oncotarget. 2016 Jun 14;7(24):35932-35945.
5. Bonnin N, Armandy E, Carras J, Ferrandon S, Battiston-Montagne P, Aubry M, Guihard S, Meyronet D, Foy JP, Saintigny P, Ledrappier S, Jung A, Rimokh R, Rodriguez-Lafrasse C, Poncet D. MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma. Oncotarget. 2016 Jun 4.
6. Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN Jr, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila). 2015 Nov;8(11):1027-35.
7. Foy JP, Bertolus C, William NW, Saintigny P. Oral premalignancy – The roles of early detection and chemoprevention. Otolaryngologic Clinics of North America. 2013 Aug;46(4):579-97.
8. Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, Lippman SM, Girard L, Minna JD, Heymach JV, Johnson FM. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther. 2012 Sep;11(9):2021-32.
9. Taoudi Benchekroun M*, Saintigny P*, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila). 2010 Jul;3(7):800-9.
10. Tao L, Lefèvre M, Ricci S, Saintigny P, Callard P, Périé S, Lacave R, Bernaudin JF, Lacau St Guily J. Detection of occult carcinomatous diffusion in lymph nodes from head and neck squamous cell carcinoma using real-time RT-PCR detection of cytokeratin 19 mRNA. Br J Cancer. 2006 Apr 24;94(8):1164-9.
11. William WN Jr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb 1;2(2):209-16.
12. Blumenschein GR Jr*, Saintigny P*, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J Jr, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15;19(24):6967-75.
13. Saintigny P*, Massarelli E*, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O’Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res. 2013 Jan 15;73(2):571-82.
14. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors andidentifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 1;19(1):279-90.
15. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 8;104(3):228-39.
16. Saintigny P, Zhang L, Fan YH, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W, Mao L. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011 Feb;4(2):218-29.
17. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM, Mao L. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009 Oct 1;15(19):6284-91.
18. Saintigny P, Besse B, Callard P, Vergnaud AC, Czernichow S, Colombat M, Girard P, Validire P, Breau JL, Bernaudin JF, Soria JC. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res. 2007 Aug 15;13(16):4825-31.
19. Saintigny P, Kambouchner M, Ly M, Gomes N, Sainte-Catherine O, Vassy R, Czernichow S, Letoumelin P, Breau JL, Bernaudin JF, Kraemer M. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer. 2007 Nov;58(2):205-13.

20.       Saintigny P, Coulon S, Kambouchner M, Ricci S, Martinot E, Danel C, Breau JL, Bernaudin JF. Real-time RT-PCR detection of CK19, CK7 and MUC1 mRNA for diagnosis of lymph node micrometastases in non-small cell lung carcinoma